In the phase III ULTIMATE trial,19 166 patients with advanced NSCLCs progressing after first- or second-line therapy were randomized to receive weekly the paclitaxelCBVZ combination compared to docetaxel; progression-free survival (PFS) was significantly longer for the former group but overall survival (OS) was comparable for the two groups

In the phase III ULTIMATE trial,19 166 patients with advanced NSCLCs progressing after first- or second-line therapy were randomized to…